Talk to the press office
Chrystal Loyer
Fareon, Inc. · San Francisco, CA · fareon.co
Company boilerplate
For use in coverage. Please reproduce verbatim where possible.
Fareon is pioneering a new class of biophysics therapies designed to noninvasively treat brain disorders through precisely calibrated electromagnetic fields. The company’s Fareon Restore platform delivers proprietary Microtesla Magnetic Therapy (MMT) in order to activate biological pathways associated with resolution of inflammation and oxidative stress, repair, and recovery in the brain. In clinical trials, MMT has been delivered through a lightweight Fareon Restore headset connected to a tabletop console.
Working alongside leading academic and clinical collaborators, Fareon combines biophysics, high-content imaging and AI to systematically map how physical fields influence biology, accelerating the discovery of therapeutic signals and their translation from cellular models to patients. A public benefit corporation, Fareon is developing therapies for clinical populations where existing treatment options remain limited. The company’s lead product is intended to be administered comfortably in an outpatient or home setting and has been well tolerated in clinical studies to date.
Learn more at fareon.co.
MMT is an investigational device. It has not been cleared by the U.S. Food and Drug Administration, and is not available for sale. Safety and effectiveness findings of the first-in-human feasibility study (n=30) are to be established in larger controlled trials.
Fareon at a glance
| Company | Fareon, Inc. — a Delaware public benefit corporation |
|---|---|
| Headquarters | San Francisco, California |
| What it makes | Microtesla Magnetic Therapy (MMT): a noninvasive, at-home biophysics therapy delivering low-intensity radiofrequency magnetic fields via a wearable headset and console |
| Lead indication | Cognitive impairment from Long COVID (“brain fog”) |
| Clinical status | Investigational device. First-in-human feasibility study completed (2026, Mount Sinai, n=30: 20 active / 10 sham); multicenter study planned for late 2026 / early 2027 |
| Evidence to date | Zero serious adverse events; preliminary improvements in cognition and mood; plasma proteomic remodeling (SomaScan 11K). Peer-reviewed mechanism in iScience (Cell Press, 2026) |
| Leadership | Blake Gurfein, PhD (Founder & CEO); David Maltz, MS, MBA (Founding CPO); Nathan Brady, PhD (Founding Head of Research) |
| Support & partners | Philanthropy: Resonance Philanthropies, Baszucki Group, Zabara Foundation. Academic: Mount Sinai, UCSF |
| Website | fareon.co |
Editors: company founding year, total funding raised, and headcount are not included pending confirmation.
Logos
Complete kits — Illustrator, PDF and PNG, in oxford, mint, white and aluminum. Please do not alter the logo or its colors.
Published & preprint
Fareon advances its science in the open. Peer-reviewed and preprint sources for fact-checking:
Please distinguish peer-reviewed (iScience) from preprint (medRxiv) sources in coverage.